Abstract
To keep ischemic brain cells alive, neuroprotective agents target events in the ischemic cascade that might be injurious to the cells. They can be divided broadly into groups that restore ion balance, block receptors, prevent reperfusion injury, or promote neuronal healing. To date, neuroprotective agents have either shown a lack of efficacy in clinical stroke trials or been limited by side effects. Ongoing clinical trials with novel agents are trying to enroll a more homogeneous population of stroke patients in an effort to demonstrate treatment benefit.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-18 |
| Number of pages | 6 |
| Journal | Current Neurology and Neuroscience Reports |
| Volume | 1 |
| Issue number | 1 |
| State | Published - Jan 2001 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Neuroscience(all)
Cite this
Current status of neuroprotective agents in the treatment of acute ischemic stroke. / Lutsep, Helmi; Clark, Wayne.
In: Current Neurology and Neuroscience Reports, Vol. 1, No. 1, 01.2001, p. 13-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current status of neuroprotective agents in the treatment of acute ischemic stroke.
AU - Lutsep, Helmi
AU - Clark, Wayne
PY - 2001/1
Y1 - 2001/1
N2 - To keep ischemic brain cells alive, neuroprotective agents target events in the ischemic cascade that might be injurious to the cells. They can be divided broadly into groups that restore ion balance, block receptors, prevent reperfusion injury, or promote neuronal healing. To date, neuroprotective agents have either shown a lack of efficacy in clinical stroke trials or been limited by side effects. Ongoing clinical trials with novel agents are trying to enroll a more homogeneous population of stroke patients in an effort to demonstrate treatment benefit.
AB - To keep ischemic brain cells alive, neuroprotective agents target events in the ischemic cascade that might be injurious to the cells. They can be divided broadly into groups that restore ion balance, block receptors, prevent reperfusion injury, or promote neuronal healing. To date, neuroprotective agents have either shown a lack of efficacy in clinical stroke trials or been limited by side effects. Ongoing clinical trials with novel agents are trying to enroll a more homogeneous population of stroke patients in an effort to demonstrate treatment benefit.
UR - http://www.scopus.com/inward/record.url?scp=0035240265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035240265&partnerID=8YFLogxK
M3 - Article
C2 - 11898495
AN - SCOPUS:0035240265
VL - 1
SP - 13
EP - 18
JO - Current Neurology and Neuroscience Reports
JF - Current Neurology and Neuroscience Reports
SN - 1528-4042
IS - 1
ER -